Compare PBI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBI | ORKA |
|---|---|---|
| Founded | 1920 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | PBI | ORKA |
|---|---|---|
| Price | $10.17 | $30.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $11.67 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 2.8M | 412.0K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,931,125,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.88 | $5.49 |
| 52 Week High | $13.11 | $32.28 |
| Indicator | PBI | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 55.51 | 55.78 |
| Support Level | $9.70 | $29.38 |
| Resistance Level | $10.26 | $32.28 |
| Average True Range (ATR) | 0.23 | 1.63 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 82.66 | 62.17 |
Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.